Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.

Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study.

Long-term use of statins has been reported to reduce the risk of death in patients with lung cancer. This study investigated the effect of statin use among patients with lung cancer receiving epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKIs) therapy. A nationwide, population-bas...

Full description

Bibliographic Details
Main Authors:	Ming-Szu Hung, I-Chuan Chen, Chuan-Pin Lee, Ru-Jiun Huang, Pau-Chung Chen, Ying-Huang Tsai, Yao-Hsu Yang
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2017-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC5291515?pdf=render

Similar Items

The Impact of Sequence of Chemotherapy and EGFR-TKI Treatment on Different EGFR Mutation Lung Adenocarcinoma
by: Fu-Tsai Chung, et al.
Published: (2015-01-01)

Effect of EGFR-TKI on Lymphangiogenesis of Lung Cancer with EGFR Mutation
by: Minghui CAI, et al.
Published: (2014-12-01)

Characterization of the Small Compounds -T315 on EGFR Degradation in EGFR-TKI Resistant Lung Adenocarcinoma
by: Kuo-Yen Huang, et al.
Published: (2015)

Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI
by: Guo-Hao Xia, et al.
Published: (2014-12-01)

Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
by: Hsu KH, et al.
Published: (2021-03-01)

EGFR-TKI plus bevacizumab versus EGFR-TKI monotherapy for patients with EGFR mutation-positive advanced non-small cell lung cancer-A propensity score matching analysis
by: Jeng-Shiuan Tsai, et al.
Published: (2021-09-01)

EGFR plasma mutation in prediction models for resistance with EGFR TKI and survival of non-small cell lung cancer
by: Thang Thanh Phan, et al.
Published: (2019-01-01)

Crosstalk of EGFR-TKI resistance with stem cell signalling in lung cancer
by: Hsu Yun, et al.
Published: (2015)

The Impact of Acquired EGFR T790M Mutation and EGFR Circulating Cell-Free DNA on Survival in Patients with Lung Adenocarcinoma Following EGFR-TKI Therapy
by: Cheng WC, et al.
Published: (2021-01-01)

Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
by: Yoshihito Kogure, et al.
Published: (2015-01-01)

Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs
by: Ming-Szu Hung MD, PhD, et al.
Published: (2019-08-01)

Molecular and Clinical Features of EGFR-TKI-Associated Lung Injury
by: Tohru Ohmori, et al.
Published: (2021-01-01)

Overexpression of RhoV Promotes the Progression and EGFR-TKI Resistance of Lung Adenocarcinoma
by: Hongjin Chen, et al.
Published: (2021-03-01)

Role of AKT3 in EGFR-TKI Resistance of Non-Small Cell Lung Cancer
by: Shih-Hsiang Huang, et al.
Published: (2018)

EGFR-TKI-based vs non-EGFR-TKI-based adjuvant therapy in resected non-small-cell lung cancer with EGFR mutations: a meta-analysis of randomized controlled trials
by: Wu JX, et al.
Published: (2018-10-01)

Clinical study of apatinib combined with EGFR‐TKI in the treatment of chronic progression after EGFR‐TKI treatment in non‐small cell lung cancer (ChiCTR1800019185)
by: Xin Li, et al.
Published: (2020-03-01)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
by: Fangqiu Fu, et al.
Published: (2021-04-01)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
by: Qiming Wang, et al.
Published: (2019-06-01)

Advances in the Research of Autophagy in EGFR-TKI Treatment and Resistance  in Lung Cancer
by: Qicheng ZHANG, et al.
Published: (2016-09-01)

Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma
by: Da Hyun Kang, et al.
Published: (2020-06-01)

Postoperative survival of EGFR-TKI-targeted therapy in non-small cell lung cancer patients with EGFR 19 or 21 mutations: a retrospective study
by: Wenjing Yang, et al.
Published: (2017-11-01)

Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
by: Seo Yun Kim, M.D., et al.
Published: (2019-01-01)

Co-administration of 20(S)-protopanaxatriol (g-PPT) and EGFR-TKI overcomes EGFR-TKI resistance by decreasing SCD1 induced lipid accumulation in non-small cell lung cancer
by: Quanfu Huang, et al.
Published: (2019-03-01)

Concurrent use of anlotinib overcomes acquired resistance to EGFR‐TKI in patients with advanced EGFR‐mutant non‐small cell lung cancer
by: Chen Zhang, et al.
Published: (2021-10-01)

An Observational Study of Acquired EGFR T790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
by: Shang-Gin Wu, et al.
Published: (2020-09-01)

Hedgehog pathway improves cell survival against EGFR-TKI treatment through induction of HGF and AKT in lung adenocarcinoma
by: Sheng-Ping Yang, et al.
Published: (2014)

Treatment Choice After EGFR-TKI Resistance
by: Junling LI
Published: (2013-10-01)

Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma
by: Lv Y, et al.
Published: (2016-01-01)

Therapeutic effect of whole brain radiotherapy on advanced NSCLC between EGFR TKI-naïve and TKI-resistant
by: Lihao Zhao, et al.
Published: (2019-12-01)

Bisphosphonate Zoledronic Acid Enhances the Inhibitory Effect of EGFR-TKI Gefitinib on Non-small Cell Lung Carcinoma Cells in vitro and in vivo
by: Chia-Chuan Hsieh, et al.
Published: (2008)

Overall survival in EGFR mutated non-small-cell lung cancer patients treated with afatinib after EGFR TKI and resistant mechanisms upon disease progression.
by: A J van der Wekken, et al.
Published: (2017-01-01)

Relationship between ID1 and EGFR-TKI Resistance  in Non-small Cell Lung Cancer
by: Yuchen BAO, et al.
Published: (2016-12-01)

EGFR-TKI-sensitive mutations in lung carcinomas: are they related to clinical features and CT findings?
by: Qin X, et al.
Published: (2018-10-01)

The Significance of MMP-1 in EGFR-TKI–Resistant Lung Adenocarcinoma: Potential for Therapeutic Targeting
by: Ryoko Saito, et al.
Published: (2018-02-01)

Targeting YAP‐p62 signaling axis suppresses the EGFR‐TKI‐resistant lung adenocarcinoma
by: Hee Sun Park, et al.
Published: (2021-02-01)

Study of Mechanisms of Resistance to EGFR-TKI in Non-small Cell Lung Cancer with EGFR L858R Mutation
by: Hsieh, Jia-Juan, et al.
Published: (2019)

Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21
by: Jiang-Yong Yu, et al.
Published: (2016-03-01)

Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations
by: Zhang R, et al.
Published: (2016-01-01)

Overcoming T790M mutant small cell lung cancer with the third‐generation EGFR‐TKI osimertinib
by: Kejing Tang, et al.
Published: (2019-02-01)

Crizotinib with or without an EGFR-TKI in treating EGFR-mutant NSCLC patients with acquired MET amplification after failure of EGFR-TKI therapy: a multicenter retrospective study
by: Wenxian Wang, et al.
Published: (2019-02-01)